<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311480</url>
  </required_header>
  <id_info>
    <org_study_id>V87P1</org_study_id>
    <secondary_id>Eudract:2005-005871-14</secondary_id>
    <nct_id>NCT00311480</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects</brief_title>
  <official_title>A Phase II, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 7.5 mg or 15 mg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study aims to evaluate safety and immunogenicity of two doses, administered three
      weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1
      influenza antigen, in non-elderly adult and elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CPMP criteria for evaluation of flu vaccines e.g. Seroprotection, GMT's and Seroconversion rate at day 0 and day 22 and day 43 following vaccination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited Local and Systemic Reactions Within 6 Days Following Each Vaccination And Adverse Events Thought the Study.</measure>
  </secondary_outcome>
  <enrollment>520</enrollment>
  <condition>Pandemic Influenza Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine surface antigen adjuvanted with MF59</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers 18 years of age or older

        Exclusion Criteria:

          -  any auto-immune disease or other serious acute, chronic or progressive disease

          -  hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the vaccine.

          -  history of neurological symptoms or signs, or anaphylactic shock following
             administration of any vaccine.

          -  within the past 7 days, they have experienced: any acute disease, infections requiring
             systemic antibiotic or antiviral therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Drug Information Services</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G. D'Annunzio University</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Health Sciences</name>
      <address>
        <city>Genoa</city>
        <zip>16129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Lanciano-Vasto</name>
      <address>
        <city>Lanciano</city>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>March 12, 2007</last_update_submitted>
  <last_update_submitted_qc>March 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2007</last_update_posted>
  <keyword>influenza</keyword>
  <keyword>pandemic influenza</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>adjuvanted influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

